The right amount of chemotherapy in non-curable disease

Insights from health economics

Jeffrey S Hoch, Jaclyn Beca, Charlotte Chamberlain, Kelvin K.W. Chan

Research output: Contribution to journalArticle

Abstract

This article applies concepts from health economics to address what is the “right” amount of chemotherapy in non-curable disease. A health economics perspective is beneficial because it forces a focus on objectives and constraints. We review and apply the concepts of “Choice of Comparator”, “Use of QALYs” and “Equating Marginal Benefit to Marginal Cost”, demonstrating their fit for purpose when considering the optimal amount of chemotherapy for non-curable disease. Many efforts underway to improve healthcare can be viewed as applications of these key economic principles. The true value is in the concepts themselves and not in the associated calculations. Given the difference between a population and a patient perspective, different “optimal” amounts of chemotherapy may exist. For many, however, best may not be most. Optimal decisions may vary depending on whether the goal of treatment is to maximize hope or health.

Original languageEnglish (US)
Pages (from-to)30-35
Number of pages6
JournalJournal of Cancer Policy
Volume10
DOIs
StatePublished - Dec 1 2016

Fingerprint

Economics
Drug Therapy
Health
Quality-Adjusted Life Years
Delivery of Health Care
Costs and Cost Analysis
Population
Therapeutics

Keywords

  • Cost-effectiveness analysis
  • Economic evaluation
  • Health economics
  • Marginal
  • QALYs

ASJC Scopus subject areas

  • Oncology
  • Health Policy

Cite this

The right amount of chemotherapy in non-curable disease : Insights from health economics. / Hoch, Jeffrey S; Beca, Jaclyn; Chamberlain, Charlotte; Chan, Kelvin K.W.

In: Journal of Cancer Policy, Vol. 10, 01.12.2016, p. 30-35.

Research output: Contribution to journalArticle

Hoch, Jeffrey S ; Beca, Jaclyn ; Chamberlain, Charlotte ; Chan, Kelvin K.W. / The right amount of chemotherapy in non-curable disease : Insights from health economics. In: Journal of Cancer Policy. 2016 ; Vol. 10. pp. 30-35.
@article{a12274cffd634d788027ba0b4f77f80e,
title = "The right amount of chemotherapy in non-curable disease: Insights from health economics",
abstract = "This article applies concepts from health economics to address what is the “right” amount of chemotherapy in non-curable disease. A health economics perspective is beneficial because it forces a focus on objectives and constraints. We review and apply the concepts of “Choice of Comparator”, “Use of QALYs” and “Equating Marginal Benefit to Marginal Cost”, demonstrating their fit for purpose when considering the optimal amount of chemotherapy for non-curable disease. Many efforts underway to improve healthcare can be viewed as applications of these key economic principles. The true value is in the concepts themselves and not in the associated calculations. Given the difference between a population and a patient perspective, different “optimal” amounts of chemotherapy may exist. For many, however, best may not be most. Optimal decisions may vary depending on whether the goal of treatment is to maximize hope or health.",
keywords = "Cost-effectiveness analysis, Economic evaluation, Health economics, Marginal, QALYs",
author = "Hoch, {Jeffrey S} and Jaclyn Beca and Charlotte Chamberlain and Chan, {Kelvin K.W.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.jcpo.2016.05.002",
language = "English (US)",
volume = "10",
pages = "30--35",
journal = "Journal of Cancer Policy",
issn = "2213-5383",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - The right amount of chemotherapy in non-curable disease

T2 - Insights from health economics

AU - Hoch, Jeffrey S

AU - Beca, Jaclyn

AU - Chamberlain, Charlotte

AU - Chan, Kelvin K.W.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - This article applies concepts from health economics to address what is the “right” amount of chemotherapy in non-curable disease. A health economics perspective is beneficial because it forces a focus on objectives and constraints. We review and apply the concepts of “Choice of Comparator”, “Use of QALYs” and “Equating Marginal Benefit to Marginal Cost”, demonstrating their fit for purpose when considering the optimal amount of chemotherapy for non-curable disease. Many efforts underway to improve healthcare can be viewed as applications of these key economic principles. The true value is in the concepts themselves and not in the associated calculations. Given the difference between a population and a patient perspective, different “optimal” amounts of chemotherapy may exist. For many, however, best may not be most. Optimal decisions may vary depending on whether the goal of treatment is to maximize hope or health.

AB - This article applies concepts from health economics to address what is the “right” amount of chemotherapy in non-curable disease. A health economics perspective is beneficial because it forces a focus on objectives and constraints. We review and apply the concepts of “Choice of Comparator”, “Use of QALYs” and “Equating Marginal Benefit to Marginal Cost”, demonstrating their fit for purpose when considering the optimal amount of chemotherapy for non-curable disease. Many efforts underway to improve healthcare can be viewed as applications of these key economic principles. The true value is in the concepts themselves and not in the associated calculations. Given the difference between a population and a patient perspective, different “optimal” amounts of chemotherapy may exist. For many, however, best may not be most. Optimal decisions may vary depending on whether the goal of treatment is to maximize hope or health.

KW - Cost-effectiveness analysis

KW - Economic evaluation

KW - Health economics

KW - Marginal

KW - QALYs

UR - http://www.scopus.com/inward/record.url?scp=84995892149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995892149&partnerID=8YFLogxK

U2 - 10.1016/j.jcpo.2016.05.002

DO - 10.1016/j.jcpo.2016.05.002

M3 - Article

VL - 10

SP - 30

EP - 35

JO - Journal of Cancer Policy

JF - Journal of Cancer Policy

SN - 2213-5383

ER -